Stocktoria

Vaxcyte, Inc. PCVX

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-06-12 · LEI

Vaxcyte, Inc. statistics & valuation

Market cap$8.2B
P / B3.0×
Return on equity-28.5%
Return on capital-33%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2019202020212022202320242025
Operating margin (%)
2019202020212022202320242025
Return on equity (%)
-25.80% -35.20% -23.40% -32.40% -14.00% -28.50% 2019202020212022202320242025
Shares outstanding
4.1M 51.1M 53.0M 79.5M 97.2M 124.9M 136.1M 2019202020212022202320242025
Net debt ($)
2019202020212022202320242025
Share buybacks ($)
2019202020212022202320242025
Return on assets (%)
-76.50% -22.70% -30.90% -22.20% -28.60% -13.20% -25.50% 2019202020212022202320242025
Free cash flow margin (%)
2019202020212022202320242025
Debt / equity (×)
2019202020212022202320242025
EPS ($)
-$3.02 -$1.93 -$3.44 -$4.14 -$3.80 -$5.63 2019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Return on assets-25.5%-13.2%-28.6%-22.2%-30.9%-22.7%-76.5%
Return on equity-28.5%-14.0%-32.4%-23.4%-35.2%-25.8%47.3%
Current ratio7.9112.757.5423.268.938.305.58

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.